Anti-IGF-1 monoclonal antibody
Alternative Names: αIR-3Latest Information Update: 02 Jul 2023
Price :
$50 *
At a glance
- Originator
- Developer GSK; National Cancer Institute (USA)
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Insulin-like growth factor I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 25 Jan 2001 No-Development-Reported for Solid tumours in Italy (Parenteral)
- 25 Jan 2001 No-Development-Reported for Solid tumours in USA (Parenteral)
- 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline